Suppr超能文献

老年住院患者 Lund 综合药物管理模式(LIMM)的卫生经济评价。

Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital.

机构信息

Swedish Institute for Health Economics, Lund, Sweden.

出版信息

BMJ Open. 2013 Jan 10;3(1):e001563. doi: 10.1136/bmjopen-2012-001563.

Abstract

OBJECTIVE

To evaluate the cost effectiveness of a multidisciplinary team including a pharmacist for systematic medication review and reconciliation from admission to discharge at hospital among elderly patients (the Lund Integrated Medicines Management (LIMM)) in order to reduce drug-related readmissions and outpatient visits.

METHOD

Published data from the LIMM project group were used to design a probabilistic decision tree model for evaluating tools for (1) a systematic medication reconciliation and review process at initial hospital admission and during stay (admission part) and (2) a medication report for patients discharged from hospital to primary care (discharge part). The comparator was standard care. Inpatient, outpatient and staff time costs (Euros, 2009) were calculated during a 3-month period. Dis-utilities for hospital readmissions and outpatient visits due to medication errors were taken from the literature.

RESULTS

The total cost for the LIMM model was €290 compared to €630 for standard care, in spite of a €39 intervention cost. The main cost offset arose from avoided drug-related readmissions in the Admission part (€262) whereas only €66 was offset in the Discharge part as a result of fewer outpatient visits and correction time. The reduced disutility was estimated to 0.005 quality-adjusted life-years (QALY), indicating that LIMM was a dominant alternative. The probability that the intervention would be cost-effective at a zero willingness to pay for a gained QALY compared to standard care was estimated to 98%.

CONCLUSIONS

The LIMM medication reconciliation (at admission and discharge) and medication review was both cost-saving and generated greater utility compared to standard care, foremost owing to avoided drug-related hospital readmissions. When implementing such a review process with a multidisciplinary team, it may be important to consider a learning curve in order to capture the full advantage.

摘要

目的

评估一个多学科团队(包括药剂师)在医院内为老年患者(伦德综合药物管理[LIMM])进行系统药物审查和用药重整的成本效益,以减少药物相关的再入院和门诊就诊次数。

方法

使用来自 LIMM 项目组的已发表数据来设计一个概率决策树模型,用于评估(1)初始入院和住院期间(入院部分)的系统药物重整和审查流程,以及(2)从医院出院到初级保健的药物报告(出院部分)的工具。对照组为标准护理。在 3 个月期间计算了住院、门诊和员工时间成本(欧元,2009 年)。药物错误导致的住院和门诊就诊的非使用效用来自文献。

结果

LIMM 模型的总成本为 290 欧元,而标准护理为 630 欧元,尽管干预成本为 39 欧元。主要的成本节省来自入院部分的药物相关再入院减少(262 欧元),而由于门诊就诊次数和更正时间减少,出院部分仅节省 66 欧元。减少的非使用效用估计为 0.005 个质量调整生命年(QALY),表明 LIMM 是一种优势选择。与标准护理相比,干预措施在零意愿支付一个获得的 QALY 的情况下具有成本效益的概率估计为 98%。

结论

与标准护理相比,LIMM 的药物重整(入院和出院)和药物审查既节省成本又增加了效用,主要是因为避免了药物相关的住院再入院。在实施这种多学科团队审查流程时,考虑学习曲线以充分利用其优势可能很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a760/3553390/8624f4e0b71c/bmjopen2012001563f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验